Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Long-term effects of rituximab in rheumatoid arthritis: clinical, biologic, and pharmacogenetic aspects.

Annals of the New York Academy of Sciences - 1 Sept 2009

Quartuccio Luca, Lombardi Sandra, Fabris Martina, Masolini Paola, Saracco Marta, Pellerito Raffaele, De Vita Salvatore

Abstract excerpt

Rituximab selectively targets the B-cell compartment, including rheumatoid factor-positive B cells. Short-term efficacy and safety of rituximab in rheumatoid arthritis (RA) has been established by multicenter randomized placebo-controlled studies. Results of long-term follow-up of the phase II/III clinical trials have confirmed the efficacy and safety of repeated courses of rituximab in the responders. However,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal
Share to Antibodies, Monoclonal, Murine-Derived

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Antigens, CD20

Share to Antirheumatic Agents

Share to Arthritis, Rheumatoid

Share to B-Lymphocytes

Share to Receptors, IgG

Share to Rituximab

Source

Identifiers

PMID: 19758217
DOI: 10.1111/j.1749-6632.2009.04668.x

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Long-term effects of rituximab in rheumatoid arthritis: clinical, biologic, and pharmacogenetic aspects.PMID 19758217Read ↗

Short- and long-term effects of anti-CD20 treatment on B cell ontogeny in bone marrow of patients with rheumatoid arthritis.Semantic proximity Read ↗

Predictive factors of response to biological disease modifying antirheumatic drugs: towards personalized medicine.Semantic proximity Read ↗

Sensitive B-cell receptor repertoire analysis shows repopulation correlates with clinical response to rituximab in rheumatoid arthritisSemantic proximity Read ↗

Long-term safety of rituximab in patients with rheumatic diseases and chronic or resolved hepatitis B virus infectionSemantic proximity Read ↗

The role of B cells in the pathogenesis of rheumatoid arthritis.Semantic proximity Read ↗

Real-World Use of Rituximab in Rheumatoid Arthritis: A 3-Year Analysis from the RBSMR Biologic RegistrySemantic proximity Read ↗

B-cell phenotype and IgD-CD27- memory B cells are affected by TNF-inhibitors and tocilizumab treatment in rheumatoid arthritis.Semantic proximity Read ↗

Biologic Drugs for Rheumatoid Arthritis in the Context of Biosimilars, Genetics, Epigenetics and COVID-19 TreatmentSemantic proximity Read ↗

The effect of gene polymorphisms on patient responses to rheumatoid arthritis therapy.Semantic proximity Read ↗

The role of the FcGRIIIa polymorphism in modifying the association between treatment and outcome in patients with rheumatoid arthritis treated with rituximab versus TNF-α antagonist therapies.Semantic proximity Read ↗

Rituximab in Systemic Lupus Erythematosus: Transient Effects on Autoimmunity Associated Lymphocyte Phenotypes and Implications for Immunogenicity.Semantic proximity Read ↗

Association between -871C>T promoter polymorphism in the B-cell activating factor gene and the response to rituximab in rheumatoid arthritis patients.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.